Form 4 Akoya Biosciences, Inc. For: Jun 04 Filed by: SCHNETTLER THOMAS P
![SEC EDGAR](../../../Content/images/providers/SC.png)
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: SEC EDGAR
![SEC EDGAR](../../../Content/images/providers/SC.png)
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences, Inc. (NASDAQ: AKYA) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $7.50 price target on the stock.MarketBeat
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- We Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Compensation [Yahoo! Finance]Yahoo! Finance
- NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! FYahoo! F
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $10.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
AKYA
Earnings
- 5/13/24 - Miss
AKYA
Sec Filings
- 6/12/24 - Form 4
- 6/11/24 - Form 144
- 6/7/24 - Form 4
- AKYA's page on the SEC website